Clinical Trials Logo

Conjunctivitis, Bacterial clinical trials

View clinical trials related to Conjunctivitis, Bacterial.

Filter by:

NCT ID: NCT01877694 Completed - Clinical trials for Bacterial Conjunctivitis

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

BACTOvation™
Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.

NCT ID: NCT01740388 Terminated - Clinical trials for Bacterial Conjunctivitis

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Start date: February 2013
Phase: Phase 3
Study type: Interventional

To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.

NCT ID: NCT01721694 Withdrawn - Keratitis Clinical Trials

Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection

Start date: December 2012
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or conjunctivitis compared with the individual administration of azithromycin 1.5% and 0.5% Loteprednol (separately).

NCT ID: NCT01573910 Completed - Clinical trials for Bacterial Conjunctivitis

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.

NCT ID: NCT01330355 Terminated - Clinical trials for Bacterial Conjunctivitis

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days to neonatal subjects who are 31 days or younger on the day of randomization (Visit 1).

NCT ID: NCT01238783 Withdrawn - Clinical trials for Bacterial Conjunctivitis

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Start date: January 2011
Phase: Phase 2
Study type: Interventional

To assess safety and efficacy of AL-15469A 0.5% /AL-6515 0.3% Ophthalmic Suspension for treatment of bacterial conjunctivitis

NCT ID: NCT01227915 Not yet recruiting - Clinical trials for Acute Bacterial Conjunctivitis

Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate, through clinical parameters, the comparative efficacy between topical Tobracort ® (tobramycin 0.3% dexamethasone + 1% - Chemistry Lab Union) and TOBRADEX ® (tobramycin 0.3% dexamethasone + 1 % - Alcon Lab), using the percentage of improvement (sustained response rate) at the end of treatment.

NCT ID: NCT01227863 Not yet recruiting - Clinical trials for Bacterial Conjunctivitis

Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.

NCT ID: NCT01175590 Completed - Clinical trials for Bacterial Conjunctivitis

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.

NCT ID: NCT01155999 Completed - Clinical trials for Purulent Bacterial Conjunctivitis

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.